PRA Health Sciences, Inc., a leading global contract research organisation (CRO), is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1976, the company has established itself as a pivotal player in the clinical research industry, providing comprehensive services that span from Phase I to Phase IV clinical trials. PRA Health Sciences offers a unique blend of innovative solutions, including data-driven insights and advanced technology platforms, which enhance the efficiency and effectiveness of clinical development. With a strong focus on therapeutic expertise and patient-centric approaches, the company has achieved notable milestones, including significant partnerships and a robust portfolio of successful trials. Recognised for its commitment to quality and operational excellence, PRA Health Sciences continues to solidify its market position, making it a trusted partner for pharmaceutical and biotechnology companies worldwide.
How does PRA Health Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
PRA Health Sciences, Inc.'s score of 56 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2019, PRA Health Sciences, Inc. reported total carbon emissions of approximately 31,296,000 kg CO2e. This figure includes Scope 1 emissions of about 485,000 kg CO2e from stationary combustion, Scope 2 emissions of approximately 8,456,000 kg CO2e from purchased electricity, and significant Scope 3 emissions of around 22,355,000 kg CO2e primarily from business travel. PRA Health Sciences has set ambitious near-term targets to reduce its carbon footprint, aiming to achieve near-zero emissions for both Scope 1 and Scope 2 by 2025. These commitments reflect a proactive approach to climate action, aligning with industry standards for sustainability. The emissions data is cascaded from its parent company, ICON Public Limited Company, indicating a corporate commitment to environmental responsibility across its subsidiaries. This structured approach to emissions management and reduction targets positions PRA Health Sciences as a forward-thinking entity in the healthcare sector, committed to mitigating its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 3,945,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
PRA Health Sciences, Inc.'s Scope 3 emissions, which increased by 7% last year and increased significantly since 2014, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 71% of total emissions under the GHG Protocol, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
PRA Health Sciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.